CONDUCT HIT-TO-LEAD PROGRESSION STUDIES ON INTERVENTION AGENTS: VIF/APOBEC INHIBITORS

对干预药物：VIF/APOBEC 抑制剂进行 HIT-TO-LEAD 进展研究

• 批准号: 8939061
• 负责人: MARINTHA HEIL
• 金额: $ 35.17万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-18 至 2016-09-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8939061
• 关键词: Academia; Biochemical; Biological Assay; Cells; Contracts; Data; Development; Funding; HIV; Intervention; Investigational New Drug Application; Lead; Local Microbicides; National Institute of Allergy and Infectious Disease; Phase I Clinical Trials; Private Sector; Public Health; Research Personnel; Services; Source; Structure-Activity Relationship; Therapeutic; analog; base; cytotoxic; high throughput screening; inhibitor/antagonist; novel therapeutics; pre-clinical; product development; prospective; public health priorities

The development and introduction of new therapeutics and topical microbicides against HIV remains a high public health priority. To assist in filling these public health gaps, the NIAID supports preclinical development of promising therapeutic and topical microbicide candidates that emerge from academia, the private sector, or other sources. This contract provides product development services utilizing biochemical and cell-based assays in both standard and high throughput screening (HTS) formats. The services provided under this contract will assist a wide variety of investigators in obtaining critical data needed to acquire additional funding, gain prospective partnerships (either for further development or to support Phase I trials), and fulfill regulatory agency requirements for investigational new drug (IND) applications.

开发和采用新的艾滋病毒疗法和局部杀微生物剂仍然是公共卫生的一个高度优先事项。为了帮助填补这些公共卫生空白，NIAID支持来自学术界，私营部门或其他来源的有前途的治疗和局部杀微生物剂候选物的临床前开发。该合同以标准和高通量筛选（HTS）形式利用生化和细胞分析提供产品开发服务。根据本合同提供的服务将帮助各种研究人员获得获得额外资金所需的关键数据，获得潜在的合作伙伴关系（用于进一步开发或支持I期试验），并满足监管机构对研究性新药（IND）申请的要求。